NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Keros Therapeutics, Inc. (KROS) Stock Analysis

Keros Therapeutics, Inc. (KROS) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

KROS

$11.18

−$0.22 (−1.93%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare KROS with… →

KROS Key Statistics

As of Oct 21, 2026
Trading
Open
$11.40
Previous Close
$11.40
Day's Range
11.11–11.64
52-Week Range
9.69–22.55
Volume
178.14K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.12
Valuation
Market Cap
$221.67M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
14.76
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.22
Financials (FY)
Revenue (FY)
$244.06M+6,774.96%
Net Income (FY)
$87.01M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
19.83M
1-Year Return
−27.45%
Dividend and dates
Earnings Date
November 4, 2026estimated
Avg Volume
190.65K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, KROS closed at $11.18, −27.45% over 1 year.

Keros Therapeutics, Inc. (KROS) has a market capitalization of $221.67M.

In fiscal 2025, KROS reported revenue of $244.06M.

KROS Stock Return by Calendar Year

Keros Therapeutics, Inc. (KROS) return since Apr 2020: what $10,000 became

1 year
$10,000 $7,255
−27.45%
5 years
$10,000 $2,923
−70.77%
Since Apr 2020
$10,000 $5,568
−44.32%

If you had invested $10,000 in Keros Therapeutics, Inc. (KROS) at the close on April 8, 2020, the earliest close on record here, it would have been worth $5,568 at the close on October 21, 2026: −44.32% in total, −8.57% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−45.09%
2025+28.62%
2024−60.19%
2023−17.20%
2022−17.93%
2021−17.05%
2020 (partial year)+251.29%

As of October 21, 2026.

KROS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$244.06M$87.01M35.7%
2024$3.55M−$187.35M−5,277.5%
2023$151.00K−$152.99M−101,319.2%
2022$0.00−$104.68M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$244.06M—$67.57M$87.01M35.7%
2024$3.55M—−$209.60M−$187.35M−5,277.5%
2023$151.00K—−$167.54M−$152.99M−101,319.2%
2022$0.00—−$107.71M−$104.68M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

KROS Valuation vs Biotechnology Median

Median of 608 stocks
MetricKROSBiotechnology medianvs median
P/S ratio14.7613.3011% above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 13 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Keros Therapeutics, Inc. (KROS) carries a market capitalisation of $221.67M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 92 employees.

The 52-week range on file runs from $9.69 to $22.55. KROS last closed at $11.18 on October 21, 2026. That is −$0.22 (−1.93%) against the previous close. The latest close sits 15.38% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $244.06M. That is +6,774.96% against the prior fiscal year, when revenue was $3.55M. The same year closed with net income of $87.01M. Earnings per share on a trailing basis come to −3.22.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $244.06M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 14.76. On price-to-sales that is 11.02% above the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

The trailing one-year total return is −27.45%. Measured over 5 years, that is −21.81% a year compounded. The reported beta is 1.12. Daily returns over the trailing 6 years annualize to a volatility of 67.16%.

Growth & Income

The record shows no dividend for KROS.

Across the complete calendar years on file, 2025 returned +28.62% and 2024 returned −60.19%. Of the 5 complete calendar years on file, 1 finished higher. 2026 is still running; the total return is −45.09% year to date.

Peer Comparison

Keros Therapeutics, Inc. (KROS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Keros Therapeutics, Inc. KROS $221.67M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Keros Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Keros Therapeutics, Inc.

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Visit website →